2014

ONXEO ANNOUNCES THE REALIZATION OF ITS SHARE CAPITAL INCREASE WITH SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS – ONXEO OFFENTLIGGØR HERMED GENNEMFØRELSE AF AKTIEKAPITALUDVIDELSE MED FORTEGNINGSRET FOR SELSKABETS EKSISTERENDE AKTIONÆRER

Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”) announces the realization of the share capital increase with preferential subscription rights launched in France and in Denmark on November 17, 2014 of an amount of €40,741,020 by issuance of 9,053,560 new shares. ONXEO – Settlement and delivery press release Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen –…read more →

ONXEO ANNOUNCES THE GREAT SUCCESS OF ITS SHARE CAPITAL INCREASE WITH SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS – ONXEO OFFENTLIGGØR HERMED RESULTATET AF EN SÆRDELES VELLYKKET AKTIEKAPITALUDVIDELSE MED FORTEGNINGSRET FOR SELSKABETS EKSISTERENDE AKTIONÆRER

Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”) announces today the success of the capital increase with preferential subscription rights launched in France and in Denmark on November 17, 2014. ONXEO – Result press release Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO eller “Selskabet”) offentliggør hermed en vellykket gennemførelse af kapitaludvidelsen med fortegningsret for…read more →

Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag® in primary liver cancer – Onxeo offentliggør positiv anbefaling fra ekspertkomité for selskabets fase III-studie med Livatag® mod primær leverkræft

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety monitoring of the Livatag® Phase III trial has once again unanimously recommended continuing the study without modification. “Each new positive…read more →

ONXEO LAUNCHES A RIGHTS ISSUE WITH SHAREHOLDER PREFERENTIAL SUBSCRIPTION RIGHTS, FOR A MAXIMUM AMOUNT OF UP TO €41.6 MILLION (INCLUDING AN EXTENSION CLAUSE OF €5.3 MILLION) – ONXEO OFFENTLIGGØR ET UDBUD AF AKTIER MED FORTEGNINGSRET FOR SELSKABETS EKSISTERENDE AKTIONÆRER FOR ET BELØB PÅ OP TIL 41,6 MILLIONER EURO (INKLUSIV EN UDVIDELSESKLAUSUL PÅ 5,3 MILLIONER EURO)

Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, created by the merger of BioAlliance Pharma and Topotarget in July 2014, announces today in France and in Denmark the launch of a rights issue with shareholder preferential subscription rights for a gross amount of €35.4…read more →

Onxeo confirms receipt of the $25M milestone payment on Beleodaq® – Onxeo bekræfter modtagelsen af milepælsbetaling på USD 25 mio. for Beleodaq®

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq® by the FDA. Early July 2014, Beleodaq® was granted by the U.S. Food and Drug Administration (FDA)…read more →

Quarterly Information as of September 30, 2014

Quarterly Information as of September 30, 2014 – Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named Onxeo – Major advancements of company programs • Validive®: Positive preliminary top-results of the Phase II trial • Beleodaq®: Grant of U.S. marketing authorization and first sales • Livatag®: Active recruitment in the ReLive trial with nearly 35% of planned…read more →

Positive Phase II preliminary results of Validive® for the prevention of Severe Oral Mucositis in Head and Neck cancer patients

Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients • Significant reduction of incidence of severe mucositis • Improved oral mucositis related symptoms and decreased adverse events related to radiotherapy • Good Safety profile • Strong Compliance to treatment Trial Advisory Board validated data as supportive to enter into…read more →

Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium – Onxeo modtager den anden milepælsbetaling af BPIFrance-tilskuddet til udviklingen af Livatag® som led i NICE-konsortiet

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, today announces the second payment of €1.25 million from BPIFrance (ex OSEO) as a part of the funding granted to support the NICE (Nano Innovation for Cancer) consortium. NICE is the first consortium of nanomedicine stakeholders in France focused on…read more →

Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” – Corporate Governance-pris tildelt af AGEFI: Onxeo får ”Silver Governance”

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, was awarded the Silver Governance in the Corporate Governance Prize (for midcap companies) category at the Eleventh Annual Awards, held by the French economic and financial magazine AGEFI on September 24, 2014. Corporate Governance Prizes reward listed companies with the…read more →

Onxeo attends InvestorDagen 2014, the largest Danish private investor event – Onxeo deltager i InvestorDagen 2014, den største danske begivenhed for private investorer

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, attended InvestorDagen 2014, held in Copenhagen on September 17, 2014. InvestorDagen is hosted by the Danish Shareholders’ Association, an association with 12,000 members. With around 2,500 participants, InvestorDagen is the largest event for private investors in Denmark. For…read more →

Onxeo strengthens Beleodaq® patent protection in the U.S. until 2027 – Onxeo styrker patentbeskyttelsen af Beleodaq® i USA indtil 2027

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, today announced that the U.S. Patent Office will grant a new patent for Beleodaq® (Belinostat U.S. commercial name) on September 16th 2014. In addition to the existing patent, covering the chemical structure of Beleodaq®, this new patent also…read more →

Key milestones and consolidated accounts – First six months 2014 / Vigtige milepæle og koncernregnskab 1. halvår 2014

Major evolution of the Company, renamed Onxeo, resulting from the merger between BioAlliance Pharma and Topotarget Good progress of the major portfolio products Financial resources strengthened and expenses controlled Paris (France), Copenhagen (Denmark), August 1, 2014 – Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, today…read more →

Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen, Merger exchange to take place on August 5, 2014

In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo’s admission to secondary trading and official listing on NASDAQ…read more →

The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 – Final calendar for trading on both Euronext and NASDAQ OMX to be available soon

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), announce that the cross-border merger between the two companies is legally effective as of 22 July 2014 to create Onxeo, dedicated to orphan oncology diseases. BioAlliance Pharma, as the absorbing entity, will…read more →

BioAlliance Pharma announces the launch of Sitavig® in the United States by its partner Innocutis and the granting of a new U.S. Sitavig® patent

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the launch of Sitavig® (acyclovir Lauriad®) in the United States by its commercial partner, Innocutis Holdings LLC, and the granting of a new U.S. Sitavig® patent by the United States Patent and Trademark Office. A few weeks after…read more →